Kidney transplantation under FK 506 immunosuppression.

PubWeight™: 3.31‹?› | Rank: Top 1%

🔗 View Article (PMC 2979325)

Published in Transplant Proc on February 01, 1991

Authors

R Shapiro1, M Jordan, J Fung, J McCauley, J Johnston, Y Iwaki, A Tzakis, T Hakala, S Todo, T E Starzl

Author Affiliations

1: Department of Surgery, University of Pittsburgh, Pennsylvania.

Articles citing this

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71

FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37

The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32

Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23

Combined kidney/bone marrow transplantation--evidence of augmentation of chimerism. Transplantation (1995) 1.19

Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18

A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. Clin Transplant (1994) 1.15

FK506 in pediatric kidney transplantation--primary and rescue experience. Pediatr Nephrol (1995) 1.11

Tacrolimus in renal transplantation. Transplant Proc (1996) 1.10

Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest (1996) 1.06

Pediatric renal transplantation under tacrolimus-based immunosuppression. Transplantation (1999) 1.00

FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc (1991) 0.93

Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. Transplant Proc (1991) 0.90

Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. Transplant Proc (1992) 0.87

FK 506 and autoimmune disease: perspective and prospects. Autoimmunity (1992) 0.85

The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. Clin Transpl (1995) 0.85

Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy. J Clin Invest (1996) 0.83

Calcineurin serves in the circadian output pathway to regulate the daily rhythm of L-type voltage-gated calcium channels in the retina. J Cell Biochem (2012) 0.81

FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc (1993) 0.77

Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. Endocr Rev (2015) 0.76

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75

Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet. Am J Kidney Dis (1998) 0.75

Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. Transplant Proc (1991) 0.75

A prospective, randomized trial to compare tacrolimus and prednisone with and without mycophenolate mofetil in patients undergoing renal transplantation: first report. J Urol (1998) 0.75

Articles cited by this

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45

Kidney transplantation under FK 506. JAMA (1990) 7.45

Cyclosporine. N Engl J Med (1989) 5.67

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation (1987) 2.40

The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. Transplant Proc (1991) 1.41

Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients. Transplantation (1988) 1.38

Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis (1988) 1.21

Transplantation. JAMA (1989) 1.11

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 6.54

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study. Neurology (1998) 3.82

Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26